Clinical Report: Significant Response to Amivantamab Combined with Chemotherapy

Overview

This case study presents a 52-year-old male with stage IVB lung adenocarcinoma and an uncommon EGFR G719A mutation who achieved a near-complete response to amivantamab combined with chemotherapy after multiple prior treatments. The response was durable for over nine months, highlighting the potential of this combination therapy in high-risk patients.

Background

Epidermal growth factor receptor (EGFR) mutations are common in non-small cell lung cancer (NSCLC), but uncommon mutations like G719A present unique challenges in treatment. Patients with hepatic metastases and uncommon mutations often have limited therapeutic options and poor prognoses. The efficacy of amivantamab combined with chemotherapy in this context remains largely unexplored, making this case significant.

Data Highlights

No numerical data available in the article.

Key Findings

• A 52-year-old male with EGFR G719A mutation and extensive metastases showed a near-complete response to amivantamab plus chemotherapy.
• Prior treatments included afatinib, pemetrexed/carboplatin, and a quadruple regimen, all of which failed to control disease progression.
• Follow-up imaging indicated marked regression of lung mass, hepatic and brain metastases, and resolution of ascites.
• The patient's performance status improved significantly and the response lasted over nine months with manageable side effects.
• This case is the first to report a durable response to amivantamab in a patient with an uncommon EGFR mutation.

Clinical Implications

This case suggests that amivantamab combined with chemotherapy may be a viable salvage therapy for patients with EGFR G719A mutations and extensive visceral metastases. Clinicians should consider this combination for high-risk patients who have failed multiple lines of therapy, although further studies are needed to confirm these findings.

Conclusion

The observed durable response to amivantamab in this case underscores the potential of this treatment strategy in managing aggressive forms of EGFR-mutant lung cancer. Further research is warranted to validate these results in larger cohorts.

Related Resources & Content

1. ASCO Living Guideline, Version 2025.1, Journal of Clinical Oncology -- Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations
2. Phase 3 MARIPOSA-2 Study Shows RYBREVANT®▼(amivantamab) -- Reduced Risk of Disease Progression
3. the asco post — Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer
4. The ASCO Post — Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC
5. The ASCO Post — Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC
6. the asco post — New Subcutaneous Amivantamab Combo Dosing Schedule Shows Promising Safety and Efficacy in EGFR-Positive NSCLC
7. Amivantamab in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer
8. Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC
9. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1 | Journal of Clinical Oncology
10. Phase 3 MARIPOSA-2 Study Shows RYBREVANT®▼(amivantamab)
11. Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients | Scientific Reports